REG - Animalcare Group PLC - Appointment of Non-Executive Director

AnimalcareAnnouncement

10/02/2022 14:50

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220210:nRSJ3425Ba&default-theme=true

RNS Number : 3425B  Animalcare Group PLC  10 February 2022

ANIMALCARE GROUP PLC

 

(the "Company" or the "Group")

 

Appointment of Non-Executive Director

 

10 February 2022. Animalcare Group plc (AIM: ANCR), the international animal
health business, today announces the appointment of Dr Douglas Hutchens to
its Board of Directors as an Independent Non-Executive Director with immediate
effect.

 

Douglas Hutchens has held several senior positions in research and development
(R&D) and regulatory affairs at leading global animal health
companies. As part of the executive team at Bayer Animal Health, he was an
Executive Vice President and Chief Veterinary Officer where he led both drug
discovery and product development on a global basis. More recently, he has
held positions on several R&D advisory boards.

 

Before joining the animal health pharmaceutical industry, Douglas was an
Assistant Professor at the University of Illinois College of Veterinary
Medicine. There, he conducted studies for most of the major animal health
companies and participated in the development of multiple new products for
companion and production animals. Early in his career he was a practicing
veterinarian. Douglas holds a Doctor of Veterinary Medicine degree and a PhD
in pathobiology with an emphasis in immuno-parasitology from the University of
Illinois.

 

Jan Boone, Chairman of Animalcare Group plc, said: "We are delighted to
welcome Douglas to the Animalcare Group Board. Douglas brings a wealth of
expertise in veterinary medicine and R&D from leadership roles at some of
the world's biggest animal health companies. His knowledge and extensive
network will prove invaluable as we pursue our long-term growth strategy."

 

Additional Information

 

The following information is disclosed pursuant to Rule 17 and Schedule Two
paragraph (g) of the AIM Rules for Companies in relation to Douglas Eugene
Hutchens, aged 58:

 

 Current Directorships  Previous Directorships
 None                   Bayer Animal Health GmbH

As of the date of this announcement, Dr Hutchens holds no ordinary shares in
the capital of the Company. Save as disclosed above there are no additional
disclosures to be made in accordance with Rule 17 or Schedule Two paragraph
(g) of the AIM Rules for Companies.

 

Enquiries

 

 Animalcare Group plc                      +44 (0)1904 487 687

 Jenny Winter, Chief Executive Officer

 Chris Brewster, Chief Financial Officer

 Media/investor relations                  communications@animalcaregroup.com (mailto:communications@animalcaregroup.com)

 Stifel Nicolaus Europe Limited            +44 (0)20 7710 7600

(Nominated Adviser & Joint Broker)

 Ben Maddison

 Fred Walsh

 Nicholas Harland

 Nick Adams

 Panmure Gordon                            +44 (0)20 7886 2500

 (Joint Broker)

 Corporate Finance

 Freddy Crossley/Emma Earl

 Corporate Broking

 Rupert Dearden

 

About Animalcare

Animalcare Group plc is a UK AIM-listed international veterinary sales and
marketing organisation. Animalcare operates in seven countries and exports to
approximately 40 countries in Europe and worldwide. The Group is focused on
bringing new and innovative products to market through its own development
pipeline, partnerships and via acquisition.

 

For more information about Animalcare, please visit www.animalcaregroup.com
(http://www.animalcaregroup.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOADZGMZDGDGZZM